Filing Flows › Ligand Pharmaceuticals (LGND) › Guidance & outlook
Ligand Pharmaceuticals (LGND) guidance and outlook
Ligand Pharmaceuticals (LGND) raised its guidance on Oct 29, 2026: EPS $9.50–$9.75 for FY2026; Revenue $270M–$310M for FY2026. Ligand Pharmaceuticals' 10-Q filed Oct 30, 2026 makes 5 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | FY2026 | $9.50–$9.75 | raised |
| Revenue | FY2026 | $225M–$250M | new |
| Revenue | FY2026 | $270M–$310M | raised |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- This outlook represents our current judgment on the future direction of our business.
- For example, there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s), that we will be able to retain our key employees or that we will be able to enter into any strategic partnerships or other transactions.
- We cannot assure you that we will receive expected Kyprolis, Captisol and other product revenues to support our ongoing business or that our internal or partnered pipeline products will progress in their development, gain marketing approval or achieve success in the market.
- Solely for convenience, trademarks and trade names referred to in this report appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade marks and trade names.
- As of September 30, 2026, we had $38.9 million in contingent consideration liabilities, measured at fair value, related to the XOMA Acquisition and prior acquisitions, which are expected to be settled in future periods.
Ligand Pharmaceuticals' latest quarter
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Ligand Pharmaceuticals raise or lower its guidance?
Ligand Pharmaceuticals (LGND) raised its guidance on Oct 29, 2026: EPS $9.50–$9.75 for FY2026; Revenue $270M–$310M for FY2026.
What does Ligand Pharmaceuticals expect?
This outlook represents our current judgment on the future direction of our business. For example, there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s), that we will be able to retain our key employees or that we will be able to enter into any strategic partnerships or other transactions. We cannot assure you that we will receive expected Kyprolis, Captisol and other product revenues to support our ongoing business or that our internal or partnered pipeline products will progress in their development, gain marketing approval or achieve succe
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.